Cargando…
Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)
BACKGROUND: High‐dose pharmaceutical‐grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, plasma ne...
Autores principales: | Collongues, Nicolas, Kuhle, Jens, Tsagkas, Charidimos, Lamy, Julien, Meyer, Nicolas, Barro, Christian, Parmar, Katrin, Amann, Michael, Wuerfel, Jens, Kappos, Ludwig, Moreau, Thibault, de Seze, Jerome |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882156/ https://www.ncbi.nlm.nih.gov/pubmed/33314801 http://dx.doi.org/10.1002/brb3.1998 |
Ejemplares similares
-
Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
por: Tsagkas, Charidimos, et al.
Publicado: (2021) -
High-dose pharmaceutical grade biotin (MD1003) in amyotrophic lateral sclerosis: A pilot study
por: Juntas-Morales, Raul, et al.
Publicado: (2020) -
Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance
por: Tsagkas, Charidimos, et al.
Publicado: (2021) -
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016) -
Longitudinal patterns of cortical thinning in multiple sclerosis
por: Tsagkas, Charidimos, et al.
Publicado: (2020)